• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13D/A filed by Poseida Therapeutics Inc. (Amendment)

    4/25/22 4:30:55 PM ET
    $PSTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $PSTX alert in real time by email
    SC 13D/A 1 brhc10036639_sc13da.htm SC 13D/A
    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    SCHEDULE 13D

    Under the Securities Exchange Act of 1934
    (Amendment No. 1)

    Poseida Therapeutics, Inc.
    (Name of Issuer)

    Common Shares
    (Title of Class of Securities)

    73730P108
     (CUSIP Number)

    Matthew Halbower
    Pentwater Capital Management LP
    1001 10th Avenue South, Suite 216
    Naples, FL 34102
    (239) 384-9750

     (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

    April 22, 2022
     (Date of Event which Requires Filing of this Statement)

    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box ☐

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act.



    CUSIP No. 73730P108
    1
    NAMES OF REPORTING PERSONS
     
     
    Pentwater Capital Management LP
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a)
    ☐

    (b)
    ☒
     
     
    3
    SEC USE ONLY
     
     

     
     
     
     
    4
    SOURCE OF FUNDS (SEE INSTRUCTIONS)
     
     
    OO
     
     
     
     
    5
    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(D) OR 2(E)
     
    ☐

     
     
     
     
    6
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
    Delaware
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    7
    SOLE VOTING POWER
     
     
    4,967,227
     
     
     
     
    8
    SHARED VOTING POWER
     
     

     
     
     
     
    9
    SOLE DISPOSITIVE POWER
     
     
    4,967,227
     
     
     
     
    10
    SHARED DISPOSITIVE POWER
     
     

     
     
     
     
    11
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
    4,967,227
     
     
     
     
    12
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
    ☐

     
     
     
     
    13
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
     
     
    7.94%1
     
     
     
     
    14
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
    IA
     
     
     
     

    (1)
    Based on 62,546,899 shares of Common Stock outstanding as of March 4, 2022, as reported in the Issuer’s Form 10-K for the year ended December 31, 2021.


    CUSIP No. 73730P108
    1
    NAMES OF REPORTING PERSONS
     
     
    Crown Managed Accounts SPC
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a)
    ☐

    (b)
    ☒
     
     
    3
    SEC USE ONLY
     
     

     
     
     
     
    4
    SOURCE OF FUNDS (SEE INSTRUCTIONS)
     
     
    WC
     
     
     
     
    5
    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(D) OR 2(E)
     
    ☐

     
     
     
     
    6
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
    Cayman Islands
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    7
    SOLE VOTING POWER
     
     

     
     
     
     
    8
    SHARED VOTING POWER
     
     
    31,077
     
     
     
     
    9
    SOLE DISPOSITIVE POWER
     
     

     
     
     
     
    10
    SHARED DISPOSITIVE POWER
     
     
    31,077
     
     
     
     
    11
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
    31,077
     
     
     
     
    12
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
    ☐

     
     
     
     
    13
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
     
     
    0.05%1
     
     
     
     
    14
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
    OO
     
     
     
     

    (1)
    Based on 62,546,899 shares of Common Stock outstanding as of March 4, 2022, as reported in the Issuer’s Form 10-K for the year ended December 31, 2021.


    CUSIP No. 73730P108
    1
    NAMES OF REPORTING PERSONS
     
     
    Investment Opportunities 3SPC
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a)
    ☐

    (b)
    ☒
     
     
    3
    SEC USE ONLY
     
     

     
     
     
     
    4
    SOURCE OF FUNDS (SEE INSTRUCTIONS)
     
     
    WC
     
     
     
     
    5
    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(D) OR 2(E)
     
    ☐

     
     
     
     
    6
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
    Cayman Islands
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    7
    SOLE VOTING POWER
     
     

     
     
     
     
    8
    SHARED VOTING POWER
     
     
    40,896
     
     
     
     
    9
    SOLE DISPOSITIVE POWER
     
     

     
     
     
     
    10
    SHARED DISPOSITIVE POWER
     
     
    40,896
     
     
     
     
    11
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
    40,896
     
     
     
     
    12
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
    ☐

     
     
     
     
    13
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
     
     
    0.07%1
     
     
     
     
    14
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
    OO
     
     
     
     

      (1)
    Based on 62,546,899 shares of Common Stock outstanding as of March 4, 2022, as reported in the Issuer’s Form 10-K for the year ended December 31, 2021.


    CUSIP No. 73730P108
    1
    NAMES OF REPORTING PERSONS
     
     
    LMA SPC on behalf of MAP 98 Segregated Portfolio
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a)
    ☐

    (b)
    ☒
     
     
    3
    SEC USE ONLY
     
     

     
     
     
     
    4
    SOURCE OF FUNDS (SEE INSTRUCTIONS)
     
     
    WC
     
     
     
     
    5
    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(D) OR 2(E)
     
    ☐

     
     
     
     
    6
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
    Cayman Islands
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    7
    SOLE VOTING POWER
     
     

     
     
     
     
    8
    SHARED VOTING POWER
     
     
    274,749
     
     
     
     
    9
    SOLE DISPOSITIVE POWER
     
     

     
     
     
     
    10
    SHARED DISPOSITIVE POWER
     
     
    274,749
     
     
     
     
    11
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
    274,749
     
     
     
     
    12
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
    ☐

     
     
     
     
    13
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
     
     
    0.44%1
     
     
     
     
    14
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
    OO
     
     
     
     

      (1)
    Based on 62,546,899 shares of Common Stock outstanding as of March 4, 2022, as reported in the Issuer’s Form 10-K for the year ended December 31, 2021.


    CUSIP No. 73730P108
    1
    NAMES OF REPORTING PERSONS
     
     
    PWCM Master Fund Ltd.
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a)
    ☐

    (b)
    ☒
     
     
    3
    SEC USE ONLY
     
     

     
     
     
     
    4
    SOURCE OF FUNDS (SEE INSTRUCTIONS)
     
     
    WC
     
     
     
     
    5
    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(D) OR 2(E)
     
    ☐

     
     
     
     
    6
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
    Cayman Islands
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    7
    SOLE VOTING POWER
     
     

     
     
     
     
    8
    SHARED VOTING POWER
     
     
    1,891,819
     
     
     
     
    9
    SOLE DISPOSITIVE POWER
     
     

     
     
     
     
    10
    SHARED DISPOSITIVE POWER
     
     
    1,891,819
     
     
     
     
    11
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
    1,891,819
     
     
     
     
    12
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
    ☐

     
     
     
     
    13
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
     
     
    3.02%1
     
     
     
     
    14
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
    OO
     
     
     
     


    (1)
    Based on 62,546,899 shares of Common Stock outstanding as of March 4, 2022, as reported in the Issuer’s Form 10-K for the year ended December 31, 2021.


    CUSIP No. 73730P108
    1
    NAMES OF REPORTING PERSONS
     
     
    Oceana Master Fund Ltd.
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a)
    ☐

    (b)
    ☒
     
     
    3
    SEC USE ONLY
     
     

     
     
     
     
    4
    SOURCE OF FUNDS (SEE INSTRUCTIONS)
     
     
    WC
     
     
     
     
    5
    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(D) OR 2(E)
     
    ☐

     
     
     
     
    6
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
    Cayman Islands
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    7
    SOLE VOTING POWER
     
     

     
     
     
     
    8
    SHARED VOTING POWER
     
     
    403,094
     
     
     
     
    9
    SOLE DISPOSITIVE POWER
     
     

     
     
     
     
    10
    SHARED DISPOSITIVE POWER
     
     
    403,094
     
     
     
     
    11
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
    403,094
     
     
     
     
    12
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
    ☐

     
     
     
     
    13
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
     
     
    0.64%1
     
     
     
     
    14
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
    OO
     
     
     
     


    (1)
    Based on 62,546,899 shares of Common Stock outstanding as of March 4, 2022, as reported in the Issuer’s Form 10-K for the year ended December 31, 2021.


    CUSIP No. 73730P108
    1
    NAMES OF REPORTING PERSONS
     
     
    Pentwater Credit Master Fund Ltd.
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a)
    ☐

    (b)
    ☒
     
     
    3
    SEC USE ONLY
     
     

     
     
     
     
    4
    SOURCE OF FUNDS (SEE INSTRUCTIONS)
     
     
    WC
     
     
     
     
    5
    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(D) OR 2(E)
     
    ☐

     
     
     
     
    6
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
    Cayman Islands
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    7
    SOLE VOTING POWER
     
     

     
     
     
     
    8
    SHARED VOTING POWER
     
     
    368,210
     
     
     
     
    9
    SOLE DISPOSITIVE POWER
     
     

     
     
     
     
    10
    SHARED DISPOSITIVE POWER
     
     
    368,210
     
     
     
     
    11
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
    368,210
     
     
     
     
    12
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
    ☐

     
     
     
     
    13
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
     
     
    0.59%1
     
     
     
     
    14
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
    OO
     
     
     
     


    (1)
    Based on 62,546,899 shares of Common Stock outstanding as of March 4, 2022, as reported in the Issuer’s Form 10-K for the year ended December 31, 2021.


    CUSIP No. 73730P108
    1
    NAMES OF REPORTING PERSONS
     
     
    Pentwater Equity Opportunities Master Fund Ltd.
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a)
    ☐

    (b)
    ☒
     
     
    3
    SEC USE ONLY
     
     
     
     
     
     
     
    4
    SOURCE OF FUNDS (SEE INSTRUCTIONS)
     
     
    WC
     
     
     
     
    5
    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(D) OR 2(E)
     
    ☐

     
     
     
     
    6
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
    Cayman Islands
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    7
    SOLE VOTING POWER
     
     

     
     
     
     
    8
    SHARED VOTING POWER
     
     
    493,783
     
     
     
     
    9
    SOLE DISPOSITIVE POWER
     
     

     
     
     
     
    10
    SHARED DISPOSITIVE POWER
     
     
    493,783
     
     
     
     
    11
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
    493,783
     
     
     
     
    12
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
    ☐

     
     
     
     
    13
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
     
     
    0.79%1
     
     
     
     
    14
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
    OO
     
     
     
     


    (1)
    Based on 62,546,899 shares of Common Stock outstanding as of March 4, 2022, as reported in the Issuer’s Form 10-K for the year ended December 31, 2021.


    CUSIP No. 73730P108
    1
    NAMES OF REPORTING PERSONS
     
     
    Pentwater Merger Arbitrage Master Fund Ltd.
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a)
    ☐

    (b)
    ☒
     
     
    3
    SEC USE ONLY
     
     

     
     
     
     
    4
    SOURCE OF FUNDS (SEE INSTRUCTIONS)
     
     
    WC
     
     
     
     
    5
    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(D) OR 2(E)
     
    ☐

     
     
     
     
    6
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
    Cayman Islands
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    7
    SOLE VOTING POWER
     
     

     
     
     
     
    8
    SHARED VOTING POWER
     
     
    1,381,146
     
     
     
     
    9
    SOLE DISPOSITIVE POWER
     
     

     
     
     
     
    10
    SHARED DISPOSITIVE POWER
     
     
    1,381,146
     
     
     
     
    11
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
    1,381,146
     
     
     
     
    12
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
    ☐

     
     
     
     
    13
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
     
     
    2.21%1
     
     
     
     
    14
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
    OO
     
     
     
     


    (1)
    Based on 62,546,899 shares of Common Stock outstanding as of March 4, 2022, as reported in the Issuer’s Form 10-K for the year ended December 31, 2021.


    CUSIP No. 73730P108
    1
    NAMES OF REPORTING PERSONS
     
     
    Pentwater Metric Merger Arbitrage Fund LP
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a)
    ☐

    (b)
    ☒
     
     
    3
    SEC USE ONLY
     
     

     
     
     
     
    4
    SOURCE OF FUNDS (SEE INSTRUCTIONS)
     
     
    WC
     
     
     
     
    5
    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(D) OR 2(E)
     
    ☐

     
     
     
     
    6
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
    Cayman Islands
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    7
    SOLE VOTING POWER
     
     

     
     
     
     
    8
    SHARED VOTING POWER
     
     
    41,251
     
     
     
     
    9
    SOLE DISPOSITIVE POWER
     
     

     
     
     
     
    10
    SHARED DISPOSITIVE POWER
     
     
    41,251
     
     
     
     
    11
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
    41,251
     
     
     
     
    12
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
    ☐

     
     
     
     
    13
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
     
     
    0.07%1
     
     
     
     
    14
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
    OO
     
     
     
     


    (1)
    Based on 62,546,899 shares of Common Stock outstanding as of March 4, 2022, as reported in the Issuer’s Form 10-K for the year ended December 31, 2021.


    CUSIP No. 73730P108
    1
    NAMES OF REPORTING PERSONS
     
     
    Pentwater Unconstrained Master Fund Ltd.
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a)
    ☐

    (b)
    ☒
     
     
    3
    SEC USE ONLY
     
     

     
     
     
     
    4
    SOURCE OF FUNDS (SEE INSTRUCTIONS)
     
     
    WC
     
     
     
     
    5
    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(D) OR 2(E)
     
    ☐

     
     
     
     
    6
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
    Cayman Islands
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    7
    SOLE VOTING POWER
     
     

     
     
     
     
    8
    SHARED VOTING POWER
     
     
    41,202
     
     
     
     
    9
    SOLE DISPOSITIVE POWER
     
     

     
     
     
     
    10
    SHARED DISPOSITIVE POWER
     
     
    41,202
     
     
     
     
    11
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
    41,202
     
     
     
     
    12
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
    ☐

     
     
     
     
    13
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
     
     
    0.07%1
     
     
     
     
    14
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
    OO
     
     
     
     


    (1)
    Based on 62,546,899 shares of Common Stock outstanding as of March 4, 2022, as reported in the Issuer’s Form 10-K for the year ended December 31, 2021.


    This Amendment No. 1 to Schedule 13D (“Amendment No. 1”) is being filed with respect to the Reporting Persons’ beneficial ownership in Poseida Therapeutics, Inc. (the “Issuer”). This Amendment No. 1 supplements the Schedule 13D as previously filed on December 16, 2020 (the “Schedule 13D”). Each Item below amends and supplements the information disclosed under the corresponding Item of the Schedule 13D. Unless otherwise indicated herein, capitalized terms used but not defined in this Amendment No. 1 shall have the same meaning herein as are ascribed to such terms in the Schedule 13D. Except as set forth herein, this Amendment No. 1 does not modify any of the information previously reported by the Reporting Persons in the Schedule 13D.
     
    ITEM 4.
    PURPOSE OF THE TRANSACTION

    On December 16, 2020, Luke Corning was appointed to the board of directors of the Issuer.  Mr. Corning served as Head of Credit for Pentwater Capital at that time.  As of April 22, 2022, Mr. Corning is no longer employed by Pentwater Capital and Pentwater Capital no longer maintains Issuer board representation.


    SIGNATURES

    After reasonable inquiry and to the best of his or its knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.

    Dated: April 25, 2022

     
    PENTWATER CAPITAL MANAGEMENT LP
       
     
    By:
    Halbower Holdings, Inc., its general partner
       
     
    /s/ Matthew Halbower
     
    Name: Matthew Halbower
     
    Title: Chief Executive Officer

     
    CROWN MANAGED ACCOUNTS SPC
       
     
    By:
    Pentwater Capital Management LP, its investment manager
         
     
    By:
     Halbower Holdings, Inc., its general partner
       
     
    /s/ Matthew C. Halbower
     
    Name: Matthew C. Halbower
     
    Title: Chief Executive Officer
         
     
    INVESTMENT OPPORTUNITIES 3 SPC
       
     
    By:
    Pentwater Capital Management LP, its investment manager
         
     
    By:
     Halbower Holdings, Inc., its general partner
       
     
    /s/ Matthew C. Halbower
     
    Name: Matthew Halbower
     
    Title: Chief Executive Officer
         
     
    LMA SPC ON BEHALF OF MAP 98 SEGREGATED PORTFOLIO
       
     
    By:
    Pentwater Capital Management LP, its investment manager
         
     
    By:
     Halbower Holdings, Inc., its general partner
       
     
    /s/ Matthew C. Halbower
     
    Name: Matthew C. Halbower
     
    Title: Chief Executive Officer


     
    PWCM MASTER FUND LTD.
       
     
    By:
    Pentwater Capital Management LP, its investment manager
         
     
    By:
     Halbower Holdings, Inc., its general partner
       
     
    /s/ Matthew C. Halbower
     
    Name: Matthew C. Halbower
     
    Title: Chief Executive Officer
         
     
    OCEANA MASTER FUND LTD.
         
     
    By:
    Pentwater Capital Management LP, its investment manager
         
     
    By:
     Halbower Holdings, Inc., its general partner
       
     
    /s/ Matthew C. Halbower
     
    Name: Matthew C. Halbower
     
    Title: Chief Executive Officer
         
     
    PENTWATER CREDIT MASTER FUND LTD.
         
     
    By:
    Pentwater Capital Management LP, its investment manager
         
     
    By:
     Halbower Holdings, Inc., its general partner
       
     
    /s/ Matthew C. Halbower
     
    Name: Matthew C. Halbower
     
    Title: Chief Executive Officer
         
     
    PENTWATER EQUITY OPPORTUNITIES MASTER FUND LTD.
         
     
    By:
    Pentwater Capital Management LP, its investment manager
         
     
    By:
     Halbower Holdings, Inc., its general partner
       
     
    /s/ Matthew C. Halbower
     
    Name: Matthew C. Halbower
     
    Title: Chief Executive Officer


     
    PENTWATER MERGER ARBITRAGE FUND LTD.
       
     
     By:
    Pentwater Capital Management LP, its investment manager
         
     
     By:
    Halbower Holdings, Inc., its general partner
       
     
    /s/ Matthew C. Halbower
     
    Name: Matthew C. Halbower
     
    Title: Chief Executive Officer
         
     
    PENTWATER METRIC MERGER ARBITRAGE FUND LP
       
     
     By:
    Pentwater Capital Management LP, its investment manager
         
     
     By:
    Halbower Holdings, Inc., its general partner
       
     
    /s/ Matthew C. Halbower
     
    Name: Matthew C. Halbower
     
    Title: Chief Executive Officer
         
     
    PENTWATER UNCONSTRAINED MASTER FUND LTD.
       
     
     By:
    Pentwater Capital Management LP, its investment manager
         
     
     By:
    Halbower Holdings, Inc., its general partner
       
     
    /s/ Matthew C. Halbower
     
    Name: Matthew C. Halbower
     
    Title: Chief Executive Officer



    Get the next $PSTX alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $PSTX

    DatePrice TargetRatingAnalyst
    12/2/2024$10.00Overweight → Neutral
    Piper Sandler
    1/4/2023$15.00Buy
    H.C. Wainwright
    1/7/2022$24.00Overweight
    Cantor Fitzgerald
    More analyst ratings

    $PSTX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Malin Life Sciences Holdings Ltd closing all direct ownership in the company (SEC Form 4)

    4 - Poseida Therapeutics, Inc. (0001661460) (Issuer)

    1/10/25 4:10:32 PM ET
    $PSTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Amado Rafael closing all direct ownership in the company (SEC Form 4)

    4 - Poseida Therapeutics, Inc. (0001661460) (Issuer)

    1/8/25 2:17:50 PM ET
    $PSTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Corning Luke closing all direct ownership in the company (SEC Form 4)

    4 - Poseida Therapeutics, Inc. (0001661460) (Issuer)

    1/8/25 2:17:02 PM ET
    $PSTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $PSTX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Ikena Oncology and Inmagene Biopharmaceuticals Announce Kristin Yarema, Ph.D., as Chief Executive Officer of Merged Company

    BOSTON and SAN DIEGO, July 23, 2025 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (NASDAQ:IKNA) ("Ikena") and Inmagene Biopharmaceuticals ("Inmagene") today announced the appointment of Kristin Yarema, Ph.D. as Chief Executive Officer of ImageneBio ("Imagene"), of the combined company after the anticipated closing. "We are thrilled to welcome Dr. Yarema to the team. Kristin is bringing expertise to the team that will push the company, and our lead program, IMG-007, towards significant milestones," commented David Bonita, an Ikena director and a continuing board member of the combined company. "Her experience as a public company CEO and commercial leadership are valuable additions to this team.

    7/23/25 9:00:00 AM ET
    $IKNA
    $PSTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Bright Peak Therapeutics Appoints John Schmid to its Board of Directors

    SAN DIEGO and BASEL, Switzerland , April 17, 2025 (GLOBE NEWSWIRE) -- Bright Peak Therapeutics, a clinical-stage biotechnology company focused on discovering and developing multifunctional immunotherapies for cancer, today announced the appointment of John Schmid, a seasoned biotechnology executive, to its Board of Directors. "It is a pleasure to welcome John to our Board," said Fredrik Wiklund, Chief Executive Officer of Bright Peak Therapeutics. "John brings decades of experience and an extensive track record of success in the biotech sector. His strategic insights and financial expertise will be instrumental as we advance our clinical pipeline and scale Bright Peak for long-term succ

    4/17/25 7:00:00 AM ET
    $ANAB
    $DSGN
    $PSTX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)
    Business Services

    Poseida Therapeutics Highlights Positive Interim Phase 1 Results for P-BCMA-ALLO1 and Preclinical Data for Dual CAR-T P-CD19CD20-ALLO1 at the 66th American Society of Hematology (ASH) Annual Meeting

    Additional new profiling of patient responses from the optimized lymphodepletion arm (Arm C) show consistent P-BCMA-ALLO1 cellular expansion and persistence across subgroups New preclinical data supports P-CD19CD20-ALLO1's strong anti-cancer profile and the ongoing Phase 1 clinical trial Case study demonstrates reactivation of an autologous Poseida CAR-T therapy with a T-cell engager in patient with relapsed multiple myeloma, highlighting potential of TSCM-based CAR-T therapies to deliver a strong anti-myeloma response with long-term remission and CAR-T cell persistence SAN DIEGO, Dec. 9, 2024 /PRNewswire/ -- Poseida Therapeutics, Inc. (NASDAQ:PSTX), a clinical-stage allogeneic cell therapy

    12/9/24 12:00:00 PM ET
    $PSTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $PSTX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Poseida Therapeutics downgraded by Piper Sandler with a new price target

    Piper Sandler downgraded Poseida Therapeutics from Overweight to Neutral and set a new price target of $10.00

    12/2/24 10:07:39 AM ET
    $PSTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    H.C. Wainwright initiated coverage on Poseida Therapeutics with a new price target

    H.C. Wainwright initiated coverage of Poseida Therapeutics with a rating of Buy and set a new price target of $15.00

    1/4/23 7:49:53 AM ET
    $PSTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Cantor Fitzgerald initiated coverage on Poseida Therapeutics with a new price target

    Cantor Fitzgerald initiated coverage of Poseida Therapeutics with a rating of Overweight and set a new price target of $24.00

    1/7/22 8:13:46 AM ET
    $PSTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $PSTX
    Leadership Updates

    Live Leadership Updates

    View All

    Ikena Oncology and Inmagene Biopharmaceuticals Announce Kristin Yarema, Ph.D., as Chief Executive Officer of Merged Company

    BOSTON and SAN DIEGO, July 23, 2025 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (NASDAQ:IKNA) ("Ikena") and Inmagene Biopharmaceuticals ("Inmagene") today announced the appointment of Kristin Yarema, Ph.D. as Chief Executive Officer of ImageneBio ("Imagene"), of the combined company after the anticipated closing. "We are thrilled to welcome Dr. Yarema to the team. Kristin is bringing expertise to the team that will push the company, and our lead program, IMG-007, towards significant milestones," commented David Bonita, an Ikena director and a continuing board member of the combined company. "Her experience as a public company CEO and commercial leadership are valuable additions to this team.

    7/23/25 9:00:00 AM ET
    $IKNA
    $PSTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Bright Peak Therapeutics Appoints John Schmid to its Board of Directors

    SAN DIEGO and BASEL, Switzerland , April 17, 2025 (GLOBE NEWSWIRE) -- Bright Peak Therapeutics, a clinical-stage biotechnology company focused on discovering and developing multifunctional immunotherapies for cancer, today announced the appointment of John Schmid, a seasoned biotechnology executive, to its Board of Directors. "It is a pleasure to welcome John to our Board," said Fredrik Wiklund, Chief Executive Officer of Bright Peak Therapeutics. "John brings decades of experience and an extensive track record of success in the biotech sector. His strategic insights and financial expertise will be instrumental as we advance our clinical pipeline and scale Bright Peak for long-term succ

    4/17/25 7:00:00 AM ET
    $ANAB
    $DSGN
    $PSTX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)
    Business Services

    Poseida Therapeutics, Inc. Announces Agreement to be Acquired by Roche Holdings, Inc.

    Poseida stockholders to receive up to $13.00 per share in cash, comprised of $9.00 per share in cash at closing and a non-tradeable contingent value right (CVR) to receive up to an aggregate of $4.00 per share in cash; transaction represents total equity value of up to $1.5 billion Poseida to join the Roche Group and advance its innovative pipeline of non-viral, TSCM-rich CAR-T therapies and genetic medicines as part of Roche's Pharmaceuticals Division SAN DIEGO, Nov. 26, 2024 /PRNewswire/ -- Poseida Therapeutics, Inc. (NASDAQ:PSTX) ("Poseida"), a clinical-stage allogeneic cell therapy and genetic medicines company advancing differentiated non-viral treatments for patients with cancer, auto

    11/26/24 1:10:00 AM ET
    $PSTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $PSTX
    SEC Filings

    View All

    SEC Form 15-12G filed by Poseida Therapeutics Inc.

    15-12G - Poseida Therapeutics, Inc. (0001661460) (Filer)

    1/21/25 6:04:42 AM ET
    $PSTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SCHEDULE 13D/A filed by Poseida Therapeutics Inc.

    SCHEDULE 13D/A - Poseida Therapeutics, Inc. (0001661460) (Subject)

    1/13/25 4:05:12 PM ET
    $PSTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form EFFECT filed by Poseida Therapeutics Inc.

    EFFECT - Poseida Therapeutics, Inc. (0001661460) (Filer)

    1/13/25 12:15:09 AM ET
    $PSTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $PSTX
    Financials

    Live finance-specific insights

    View All

    Poseida Therapeutics Provides Updates and Financial Results for the Third Quarter of 2024

    Strong collaboration momentum with Roche expansion of CAR-T partnership and Astellas nomination of second solid tumor research program target  Cash flow positive for the first nine months of 2024; $130 million generated in milestone and upfront payments to-date  Presented positive interim Phase 1 results for RMAT-designated P-BCMA-ALLO1 with 91% overall response rate and differentiated safety profile in heavily pretreated relapsed/refractory BCMA-exposed and BCMA-naïve multiple myeloma patients Introduced P-BCMACD19-ALLO1 as wholly-owned program with compelling biologic rationale for autoimmune disease and hematological malignancies On track to deliver further updates across allogeneic CAR-T

    11/7/24 4:05:00 PM ET
    $PSTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Poseida Therapeutics Reports Positive Interim Phase 1 Results for Allogeneic CAR-T Therapy P-BCMA-ALLO1 with High Overall Response Rates in Heavily Pretreated Relapsed/Refractory Multiple Myeloma Patients

    Data showed a 91% ORR with P-BCMA-ALLO1 in an optimized lymphodepletion arm, including a 100% ORR in BCMA-naïve patients, and an 86% ORR in those who had received at least one prior BCMA- and/or GPRC5D-targeting treatment modality Differentiated P-BCMA-ALLO1 safety results with no dose-limiting toxicities, low rates of CRS and ICANS all Grade 2 or less and no graft vs. host disease or Parkinsonism P-BCMA-ALLO1 was recently granted Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA and is being evaluated in a Phase 1/1b clinical trial in patients with relapsed/refractory multiple myeloma who have previously received three or more prior lines of therapy Company to host we

    9/27/24 4:30:00 PM ET
    $PSTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Poseida Therapeutics to Present New Clinical Data from Phase 1 Study of Allogeneic CAR-T P-BCMA-ALLO1 in Patients with Relapsed/Refractory Multiple Myeloma at 21st International Myeloma Society Annual Meeting

    Latest data from Poseida's lead investigational allogeneic CAR-T program, which is based on the Company's unique stem cell memory T cell (TSCM) platform Company to host conference call on Saturday, September 28, 2024, at 1 PM ET / 10 AM PT to review the P-BCMA-ALLO1 Phase 1 IMS oral presentation data Poseida initiates P-BCMA-ALLO1 Phase 1b clinical trial in patients with multiple myeloma, generating $20 million payment from Roche SAN DIEGO, Sept. 5, 2024 /PRNewswire/ -- Poseida Therapeutics, Inc. (NASDAQ:PSTX), a clinical-stage allogeneic cell therapy and genetic medicines company advancing differentiated non-viral treatments for patients with cancer and rare diseases, announced today that

    9/5/24 9:00:00 AM ET
    $PSTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $PSTX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Poseida Therapeutics Inc.

    SC 13D/A - Poseida Therapeutics, Inc. (0001661460) (Subject)

    11/27/24 7:01:59 PM ET
    $PSTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G/A filed by Poseida Therapeutics Inc. (Amendment)

    SC 13G/A - Poseida Therapeutics, Inc. (0001661460) (Subject)

    6/7/24 1:30:02 PM ET
    $PSTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G/A filed by Poseida Therapeutics Inc. (Amendment)

    SC 13G/A - Poseida Therapeutics, Inc. (0001661460) (Subject)

    5/8/24 4:01:24 PM ET
    $PSTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care